PEYRONIE'S DISEASE SYMPTOM BOTHER REDUCTION IS RELATED TO PENILE CURVATURE IMPROVEMENT IN RESPONSE TO TREATMENT WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: RESULTS FROM TWO LARGE DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES

被引：0

作者：

Lipshultz, L., I ^{[1
]}

Sadeghi-Nejad, H. ^{[2
]}

Mills, J. ^{[3
]}

Tursi, J. P. ^{[4
]}

Smith, T. M. ^{[4
]}

Kaufman, G. J. ^{[4
]}

Liu, G. ^{[4
]}

Honig, S. ^{[5
]}

机构：

[1] Baylor Coll Med, Houston, TX 77030 USA

[2] Ctr Male Reprod Med, Hackensack, NJ USA

[3] Urol Ctr Colorado, Denver, CO USA

[4] Auxilium Pharmaceut, Chesterbrook, PA USA

[5] Yale Univ, Sch Med, New Haven, CT USA

来源：

JOURNAL OF SEXUAL MEDICINE | 2015年 / 12卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

075

引用

页码：128 / 128

页数：1

共 50 条

[31] Disability Severity Category Shift With Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies
Nagy, A. J.
Cohen, J. M.
Ning, X.
Ramirez-Campos, V
Janka, L.
McAllister, P.
HEADACHE, 2020, 60 : 11 - 11
[32] Celecoxib in the Treatment of Primary Dysmenorrhea: Results From Two Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Studies
Daniels, Stephen
Robbins, Jeffery
West, Christine R.
Nemeth, Mary Anne
CLINICAL THERAPEUTICS, 2009, 31 (06) : 1192 - 1208
[33] Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses:Two Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies
Swanson, Neil
Smith, Christina Cognata
Kaur, Mandeep
Goldenberg, Gary
JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (11) : 1278 - 1282
[34] Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses: Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies
Swanson, Neil
Smith, Christina Cognata
Kaur, Mandeep
Goldenberg, Gary
JOURNAL OF DRUGS IN DERMATOLOGY, 2014, 13 (02) : 166 - 169
[35] Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial in 22 Countries
Buvat, Jacques
Tesfaye, Fisseha
Rothman, Margaret
Rivas, David A.
Giuliano, Francois
EUROPEAN UROLOGY, 2009, 55 (04) : 957 - 968
[36] Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials
Gerding, Dale N.
Cornely, Oliver A.
Grill, Simon
Kracker, Hilke
Marrast, Anne Claire
Nord, Carl Erik
Talbot, George H.
Buitrago, Martha
Diaconescu, Iulian Gheorghe
de Oliveira, Claudia Murta
Preotescu, Liliana
Pullman, John
Louie, Thomas J.
Wilcox, Mark H.
LANCET INFECTIOUS DISEASES, 2019, 19 (03): : 265 - 274
[37] Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease:: A randomized placebo-controlled double-blind prospective clinical study
Riedl, CR
Sternig, P
Gallé, G
Langmann, F
Vcelar, B
Vorauer, K
Wagner, A
Katinger, H
Pflüger, H
EUROPEAN UROLOGY, 2005, 48 (04) : 656 - 661
[38] Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies
Kalviainen, Reetta
Genton, Pierre
Andermann, Eva
Andermann, Frederick
Magaudda, Adriana
Frucht, Steven J.
Schlit, Anne-Francoise
Gerard, Danielle
de la Loge, Christine
von Rosenstiel, Philipp
EPILEPSIA, 2016, 57 (02) : 210 - 221
[39] Adapalene 0.1% Lotion in the Treatment of Acne Vulgaris: Results From Two Placebo-controlled, Multicenter, Randomized Double-blind, Clinical Studies
Eichenfield, Lawrence F.
Jarratt, Michael
Schlessinger, Joel
Kempers, Steven
Manna, Vasant
Hwa, Joyce
Liu, Yin
Graeber, Michael
JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (06) : 639 - 646
[40] Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
Hilton, Said
Kestemont, Philippe
Sattler, Gerhard
Volteau, Magali
Thompson, Catherine
Andriopoulos, Bill
Prygova, Inna
Berg, Anna-Karin
Ascher, Benjamin
DERMATOLOGIC SURGERY, 2022, 48 (11) : 1198 - 1202

← 1 2 3 4 5 →